study question: Is optimal adherence to guideline recommendations in intrauterine insemination (IUI) care cost-effective from a societal perspective when compared with suboptimal adherence to guideline recommendations? summary answer: Optimal guideline adherence in IUI care has substantial economic benefits when compared with suboptimal guide-
Introduction
Health-care expenditures have increased enormously in the last decades (Anderson and Frogner, 2008) . Therefore, high-quality care consists nowadays not only of choosing the most clinically effective and safe treatment pathway, but also considering the costeffectiveness (Institute of Medicine, 2001) . In fertility care, perceived by many as elective, the delivery of cost-effective care is considered even more important. Expenditures for fertility care are high due to the increased use of advanced assisted reproduction techniques and because of complications, such as ovarian hyperstimulation syndrome, increased rates of adverse pregnancy outcomes, that are usually caused by multiple pregnancies and productivity loss (Fauser et al., 2005; Dickey, 2007; Bouwmans et al., 2008) .
Clinical practice guidelines can assist health-care professionals and patients to make better decisions about clinically effective, safe and cost-effective care. In spite of this, little is known about the link between guideline adherence and cost-effectiveness in health care in general. Moreover, the association between guideline adherence and cost-effectiveness in fertility care has not been explored, even though 80 million couples around the world are currently infertile and over 700 000 fertility treatment cycles are initiated yearly (Nachtigall, 2006; Sunderam et al. 2006) . Therefore, the study aimed to investigate if optimal adherence to guideline recommendations in fertility care is cost-effective from a societal perspective when compared with suboptimal adherence to guideline recommendations. The focus was on homologous intrauterine insemination (IUI), a frequently used fertility treatment associated with considerable expenditures and a high degree of practice variation with potential for cost saving.
Materials and Methods

Study design
Cost-effectiveness analyses were performed to investigate if optimal adherence to 4 recommendations derived from a systematically developed set of 25 guideline-based performance indicators for IUI care (Haagen et al., 2010) was cost-effective when compared with suboptimal adherence to these recommendations. Three of these recommendations proved in a prior study to be independently associated with clinical outcome of IUI care (recommendations 1 -3) (Haagen et al., 2010) , and one recommendation was expected to be an important cost driver in IUI care (recommendation 4), and, therefore, subject of the costeffectiveness analyses.
(1) 'More than 1 million motile spermatozoa should be available for IUI after sperm preparation'. (2) 'Couples with male factor or unexplained fertility problems should be offered up to 6 IUI cycles'. (3) 'Human chorionic gonadotrophin (hCG) should be administered at a dose of 5000 IU (instead of 10 000 IU)'.
(4) 'Couples with male factor fertility problems or cervical mucus hostility should be offered unstimulated IUI (IUI in natural cycles) and couples with unexplained fertility problems should be offered stimulated IUI (IUI after ovarian stimulation using gonadotrophins or oral anti-estrogens)'.
The cost-effectiveness analyses were conducted from a societal perspective.
Setting and study population
The extent of adherence to the four recommendations was assessed in a previously performed retrospective cohort study at 10 of the 91 Dutch hospitals providing IUI care (Haagen et al., 2010) . The 10 study hospitals were selected to represent a variety of settings and included one large university hospital providing tertiary care and nine public hospitals providing secondary care, including four intermediate-sized, non-university teaching hospitals, two intermediate-sized, non-teaching hospitals and three smaller, non-teaching hospitals. Patients eligible to participate in this study were defined as infertile couples, who underwent IUI treatment at these 10 hospitals during an inclusion period of 28 months, from April 2000 to August 2002. Couples were randomly selected by computer from the databases of the fertility laboratories of the 10 participating hospitals, in proportion to the size of each hospital's IUI programme (50-150 couples per hospital). The total sample consisted of 1100 infertile couples. Couples who had undergone ovulation induction therapy for ovulatory disorders or IUI treatment with donated spermatozoa and couples who had not reached the pre-specified outcome, either pregnancy or discontinuation of unsuccessful IUI treatment, in the given study period were excluded.
Data collection
Effectiveness
Relevant data about patient characteristics, such as female age, type and duration of infertility and diagnosis, process aspects and clinical outcomes of IUI care, were abstracted from medical records by two trained researchers using standardized audit forms.
Costs
Both direct and indirect medical costs as well as direct and indirect nonmedical costs of IUI care were taken into account. Medical costs included costs for staff, equipment, disposable materials, medication, sperm preparation, and workplace and overhead. All medical costs, except for sperm preparation, were variable costs. Non-medical costs were patients' travel expenses and productivity loss due to absence from work. The resources consumed were estimated by means of medical record analysis, for instance, the number of hospital visits and used dose of medication per couple per cycle; a patient survey with written questionnaires with openended questions about, for example, travel distance and mode of transportation to the hospital, who accompanied the female patient during the hospital visits, mean duration of the hospital visits, average absence from work and so on; interviews with staff members involved in IUI care, such as gynaecologists (n ¼ 3), an embryologist (n ¼ 1), laboratory staff (n ¼ 1), nurses (n ¼ 2), counter clerks (n ¼ 2), administrators (n ¼ 2) and interior decorators (n ¼ 2); and a review of hospitals' financial department reports and literature. To quantify the actual resources consumed, true costs were assessed, using an activity-based costing approach. If impossible or unavailable, charges or recommended prices were used, for instance, for medication. The societal costs of singleton or multiple pregnancy, delivery and period from birth up to 6 weeks after birth for both mother and offspring resulting from IUI treatment, and, in case no pregnancy was achieved with IUI treatment, of possible additional IVF treatment and singleton or multiple pregnancy, delivery and period from birth up to 6 weeks after birth for both mother and offspring resulting from IVF treatment were derived from a previously performed Dutch study (Fiddelers et al., 2009) .
All costs were expressed in the year 2009 euro (E) by means of the consumer price index for health-care costs in the Netherlands (http:// statline.cbs.nl).
Statistical analysis
Demographic data of the participating couples were presented as median values with ranges or as percentages in case of absolute numbers. For each recommendation, group comparisons for differences in patient characteristics between the group in which guideline adherence was optimal and the group in which guideline adherence was suboptimal were performed by Mann-Whitney U and Chi-square tests to investigate potential confounders.
The extent of adherence to the four recommendations was expressed as a performance score per couple, which was calculated as follows: the number of IUI cycles of a couple in which practice performance was consistent with a guideline recommendation was divided by the total number of IUI cycles of the couple to which the recommendation applied. Guideline adherence was considered optimal if a couple was treated in at least 90% of the IUI cycles according to a guideline recommendation. If a couple was treated in less than 90% of the IUI cycles according to a guideline recommendation, guideline adherence was considered suboptimal.
Effectiveness was defined as an ongoing pregnancy, that is, a clinical pregnancy of more than 16 weeks' gestation. A secondary outcome measure was ongoing multiple pregnancy. Live birth could not be used as an outcome measure because this outcome was unknown for a few couples, who were lost to follow-up.
The average medical and non-medical costs of IUI care were calculated in two steps. First, the resources consumed by each couple, expressed in units, were multiplied by their unit prices. Second, the costs of IUI care of individual couples were added together and divided by the total number of couples involved. Because of the skewed distribution of the cost parameters used as input for these cost calculations, the raw data were log transformed after which statistical inferences could be drawn using parametric statistical tests (ANOVA and t-tests). Average costs were presented as point estimates with 95%-confidence intervals (95%-CI).
To assess the cost-effectiveness of optimal versus suboptimal adherence to the four recommendations, the ongoing pregnancy rate per couple, the average costs of IUI care per couple and the incremental net monetary benefits (INB) were calculated. The INB place a monetary value on a clinical improvement by assigning a monetary value to the incremental benefit achieved and subtracting the incremental costs of achieving this benefit. The INB assessment is particularly useful in dominant scenarios, which means health gain in combination with a reduction in costs or, vice versa, health reduction despite higher costs. INB is defined as: Km De 2 m Dc , where K equals the maximum amount that society would be willing to pay for the incremental improvement in outcome, for instance, an ongoing pregnancy or live birth, m De represents the incremental benefit and m Dc the incremental costs. A positive INB implies that the costs of an intervention are less than the value of the additional benefit achieved. A negative INB implies that an intervention should be rejected, as its costs are higher than the value of the benefit achieved. The baseline willingness to pay for an ongoing pregnancy was estimated at E 20 000, according to the estimated willingness to pay for a live birth by Granberg et al. (Granberg et al., 1995) . The original empirical data were bootstrapped as an alternative to assuming a normal distribution. To calculate CI belonging to the INB, Fieller's theorem was applied (Heitjan, 2000) . To incorporate deterministic uncertainty surrounding the point estimates of INB, the willingness to pay for an ongoing pregnancy was varied from E 0 to E 20 000, thus taking a conservative position regarding K.
In the same manner, additional scenarios were investigated to consider the societal costs of singleton or multiple pregnancy, delivery and period from birth up to 6 weeks after birth for both mother and offspring resulting from IUI treatmen, and, in case no pregnancy was achieved with IUI treatment, of possible additional IVF treatment and singleton or multiple pregnancy, delivery and period from birth up to 6 weeks after birth for both mother and offspring resulting from IVF treatment. The proportion of couples who opted for IVF and its related technologies, if IUI treatment had not resulted in a pregnancy, were estimated at 71% and they underwent on average 2.1 IVF treatment cycles. In 71% of these couples, IVF resulted in an ongoing pregnancy and 14% of these pregnancies were multiples. These data have not been published, but were derived from another Dutch cohort study among 470 couples who had undergone IUI treatment during the same study period (Brandes et al., 2010) .
The cost-effectiveness analyses were performed for each recommendation independently, assuming ceteris paribus, that is, 'all other things were held constant'. P , 0.05 was considered statistically significant. Analyses were performed with the Statistical Programme for the Social Sciences (SPSS 16.0 for Windows, SPSS Inc., Chicago, IL, USA).
Ethical approval
The involved institutional review boards approved the study and participating couples signed an informed consent. Figure 1 shows the recruitment of eligible infertile couples for participation in the study. A total of 765 infertile couples were willing to participate, but 350 couples were excluded because the study of their medical records revealed that they had undergone ovulation induction therapy for ovulatory disorders or IUI treatment with donated spermatozoa (n ¼ 184) or they had not reached the pre-specified outcome, either ongoing pregnancy or discontinuation of unsuccessful IUI treatment, by the time the study ended (n ¼ 143), or because there was no access to their medical records (n ¼ 23). As a result, 415 infertile couples who started a total of 1803 IUI cycles were eligible for the cost-effectiveness analyses.
Results
Study population
The patient characteristics are listed in Table I . For each recommendation, the group in which guideline adherence was optimal was compared with the group in which guideline adherence was suboptimal with regard to the patient characteristics (female age, type of infertility (primary or secondary) and duration of infertility) to investigate potential confounders, and no significant differences between the groups were established.
Cost-effectiveness of guideline adherence in IUI care
Effectiveness
Adherence to the four recommendations varied between 16 and 74%. A total of 171 out of 415 couples (41%) became pregnant during IUI treatment and 140 pregnancies (82%) were ongoing. Among the 13 ongoing multiple pregnancies (9.3%) were 12 twins and one triplet (Table I) . Table II presents the cost parameters used as input for the cost calculations of IUI care, and Table III shows the calculated average medical and non-medical costs of IUI care. The total medical costs of one unstimulated IUI cycle were E 331 (95%-CI 311 -351) and the total nonmedical costs E 128 (95%-CI 117-138). Altogether, the average total costs of one unstimulated IUI cycle were estimated at E 459 (95%-CI 432-486). The average total costs of one stimulated IUI cycle were significantly higher, that is, E 1248 (95%-CI 1212-1285) using gonadotrophins and E 762 (95%-CI 726 -798) using oral anti-estrogens. Accordingly, the average total costs of one stimulated IUI cycle, using either gonadotrophins or oral anti-estrogens, were estimated at E 1038 (95%-CI 1009-1068).
Costs
Cost-effectiveness
Tables IV and V summarize the results of the assessment of the costeffectiveness of optimal versus suboptimal guideline adherence in IUI care. Table IV shows the results of the cost-effectiveness analyses concerning the costs of IUI care. With a willingness to pay E 20 000 for an ongoing pregnancy, the INB was positive for three out of the four recommendations investigated, which were sperm quality, the total number of IUI cycles and indications for IUI. In other words, optimal adherence to these guideline recommendations was costeffective and could save between E 235 and over E 11 000 per couple. Table V presents the results of the cost-effectiveness analyses in which, besides the costs of IUI care, the costs of singleton or multiple pregnancy, delivery and period from birth up to 6 weeks after birth for both mother and offspring resulting from IUI treatment and, in case no pregnancy was achieved with IUI treatment, of possible additional IVF treatment and singleton or multiple pregnancy, delivery and period from birth up to 6 weeks after birth for both mother and offspring resulting from IVF treatment were also taken into account. With a willingness to pay E 20 000 for an ongoing pregnancy, the INB was positive for three out of the four recommendations investigated, which were sperm quality, the total number of IUI cycles and dose of hCG. Optimal adherence to these guideline recommendations could save between E 645 and over E 7500 per couple. Comparing Tables IV and V revealed that optimal adherence to the guideline recommendations about sperm quality and the total number of IUI cycles became slightly less cost-effective, when the effects and costs of possible additional IVF treatment and pregnancies and deliveries were considered, as opposed to IUI care alone. Furthermore, optimal adherence to the guideline recommendation about indications for IUI was no longer cost-effective, when these additional effects and costs were included within the analyses. In contrast, optimal adherence to the guideline recommendation about the dose of hCG became cost-effective, when these effects and costs were taken into account, probably because suboptimal adherence to this recommendation, thus the administration of hCG at a dose of 10 000 IU, resulted in slightly more pregnancies, albeit predominantly multiple pregnancies, that is, 12 out of the total of 13 multiple pregnancies.
Discussion
Main findings
This study showed that optimal guideline adherence in IUI care was cost-effective for three out of the four recommendations investigated. The potential societal cost saving per couple starting with IUI treatment varied between E 645 and over E 7500, depending on the recommendation and assuming a willingness to pay E 20 000 for an ongoing pregnancy. Costs of singleton or multiple pregnancy, delivery and period from birth up to 6 weeks after birth for both mother and offspring and costs of IVF treatment were calculated according to Fiddelers et al. (Fiddelers et al., 2009). initiated each year to treat 32 000 infertile couples, this could mean a possible cost saving of at least 20 million euro yearly (Anderson et al., 2005; Ferraretti et al., 2012) .
Strengths and limitations of the study
The study is unique by comparing optimal with suboptimal care and performing the cost-effectiveness analyses from a societal perspective with empirical data. Even though the inclusion of future costs within economic evaluations of health care is recommended, this is rarely done (Drummond et al., 2005; Liljas et al., 2008) . However, this study conducted cost-effectiveness analyses in which the costs of possible additional IVF treatment, pregnancy, delivery and period from birth up to 6 weeks after birth for both mother and offspring were considered as well. Remarkably, in these analyses, adherence to most of the guideline recommendations remained cost-effective, but with lower INB than considering only the costs of IUI care. This could be explained by the fact that most other cost-effectiveness studies aimed to determine the benefit of reducing the cost driving medical care, complications or disease recurrence. The benefit of IUI treatment is the achievement of a pregnancy, a health status that consumes more costs than a non-pregnant health status. The societal costs of a singleton, and in particular, of a multiple pregnancy greatly exceed the costs of an IUI or IVF treatment cycle. Therefore, the inclusion of these future costs may have unfavourably influenced the results of the current analyses, but presents a more realistic and sustainable economic picture. Despite the innovative character and the use of empirical data from daily practice, some limitations of the study have to be addressed. First, because not all recommendations applied to all 415 included couples, smaller groups were left for some of the economic analyses, and one integrated analysis with all recommendations within one model was impossible. Nevertheless, the incremental net monetary Costs were fixed and therefore no 95%-CI were given. b P , 0.001 for comparing unstimulated IUI with stimulated IUI using gonadotrophins. c P , 0.001 for comparing unstimulated IUI with stimulated IUI using oral anti-estrogens. d P , 0.001 for comparing stimulated IUI using gonadotrophins with stimulated IUI using oral anti-estrogens.
benefit estimations might not have suffered too much from this restriction, considering their relatively small 95%-CI. Second, this study aimed to assess the cost-effectiveness of optimal versus suboptimal guideline adherence in IUI care. Optimal guideline adherence was defined as adherence to a guideline recommendation in at least 90% of the IUI cycles per couple. This cutoff point of 90% may seem arbitrary. However, in survival analysis to evaluate the association between guideline adherence and ongoing pregnancy after IUI using other cutoff points, such as 75, 80 and 85%, the survival model did not change, but just the estimates of the effect to a limited extent (Haagen et al., 2010) .
A third limitation of the study is the use of ongoing pregnancy as outcome measure as opposed to live birth. Live birth could not be used as outcome measure because this outcome was unknown for a few couples who were lost to follow-up. However, all couples who achieved a pregnancy that was still ongoing at more than 16 weeks' gestation and were not lost to follow-up ended up with a live birth. Therefore, we were not in doubt to use ongoing pregnancy as outcome measure and to estimate the baseline willingness to pay for an ongoing pregnancy at E 20 000, according to the estimated willingness to pay for a live birth by Granberg et al. (Granberg et al., 1995) . ..................................................................................................................................................................................... .....
Table IV
Cost-effectiveness of optimal versus suboptimal guideline adherence in IUI care, concerning costs of IUI care.
Guideline recommendation Effectiveness (%)
Costs ( Cost-effectiveness of guideline adherence in IUI care
Moreover, it can be questioned if the results can directly be translated to other countries as the investigations were performed in Dutch fertility practice. However, a previous study reported that most European countries do not have IUI guidelines (Haagen et al., 2006) . It can be assumed that in the absence of clinical practice guidelines, inappropriate practice variation is more extensive (Grimshaw and Russell, 1993; Woolf et al., 1999) . Therefore, our results are especially interesting for countries without guidelines for IUI care, as potential cost saving could be even higher.
Finally, the implications of the results for current IUI care can be questioned because the results were based on data from the period recent re-measurement with a subset of the original performance indicators for IUI care showed no improvement in guideline adherence in IUI care, it seems reasonable to assume that the presented results are not outdated (Mourad et al., 2008; The ESHRE Capri Workshop Group, 2009) .
Comparison with other studies
There are only a few studies published about the cost-effectiveness of guideline adherence in health care in general. One of these studies was performed by Koskinen and co-authors who investigated the impact of an intervention to improve guideline adherence regarding the treatment of acute otitis media on clinical outcomes and costs (Koskinen et al., 2006) . The cost-effectiveness was calculated for the total group of patients with a post-intervention guideline adherence rate of 78%. The incremental cost-effectiveness ratio in their study was E 205 per symptom-free patient, which means that an investment of E 205 in health care was needed to gain an additional symptomfree patient. The difference with our study is that they did not perform a cost-effectiveness analysis comparing patients receiving optimal and suboptimal care according to guideline recommendations. In addition, Harmsen and colleagues investigated the costeffectiveness of optimal care according to guideline recommendations for urinary tract infections in children when compared with current care, that is, optimal and suboptimal care mixed (Harmsen et al., 2009) . The incremental net monetary benefit of optimal care in this study ranged from E 20 to E 200, assuming a willingness to pay for a quality-adjusted life year that ranged from E 0 to E 80 000. However, outcomes in this study were based on several assumptions about cost behaviour and effects. Therefore, the robustness of the conclusions drawn in this study was limited.
A few other studies investigated the financial impact of guideline adherence from a health care point of view and concluded that treating patients according to guideline recommendations may reduce direct medical costs (Merchant et al., 2003; Quaglini et al., 2004; Vrancken et al., 2006; Robinson et al., 2006; Koskinen et al., 2006; Mak et al., 2007; Fritz et al., 2007; Balu, 2009; Hughes et al., 2009; Stiles et al., 2009; Amin et al., 2010) . However, the non-medical costs were not taken into account, even though non-medical costs can represent a considerable part of the total costs (Koopmanschap and Rutten, 1994) . In the present study, 16-28% of the costs per IUI cycle could be attributed to travel expenses and productivity loss, and the indirect costs of pain, suffering and discomfort were not even included.
Implications
In conclusion, optimal guideline adherence in IUI care has substantial economic benefits. Therefore, it is valuable to make an effort to improve guideline development and implementation.
A promising strategy to improve guideline development involves shared guideline development in which a central body with expertise in up-to-date guideline development methodology and sufficient resources selects the best scientific evidence available to support guideline recommendations (Haagen et al., 2006) . Then, the centrally selected evidence is shared internationally in the form of evidence tables, summarizing the content of the selected studies and indicating the level of evidence according to validated evidence-level structures. For high-quality guidelines, a transparent and explicit guideline development process that meets the internationally accepted quality criteria provided by the Appraisal of Guidelines for Research and Evaluation Enterprise is important (Brouwers et al., 2010) . This strategy may very well increase the number and quality of guidelines, giving individual health-care professionals and patients better access to the latest standards of clinical practice and reduce duplication of effort and inefficient use of resources. Interestingly, in the field of reproductive medicine, the European Society of Human Reproduction and Embryology has adopted this framework, initiating European collaboration in guideline development, and their efforts seem to pay off (Haagen et al., 2006) .
Then again, development and dissemination of guidelines do not guarantee their implementation in daily practice (Grimshaw et al., 2004) . Guideline implementation could be promoted by including a clear description of the advantages of guideline adherence in the guideline itself. For example, that optimal adherence to the guideline recommendations regarding sperm quality, the total number of IUI cycles and the dose of hCG is cost-effective. Another approach targeted at health-care professionals is giving feedback about the benefits of adherence to guideline recommendations, particularly the improved cost-effectiveness.
Moreover, the cost-effectiveness of guideline adherence should be more often the subject of investigations to gain more insight into practice variation and potential cost saving in health care.
